Kernicterus Treatment Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The kernicterus treatment market size has grown steadily in recent years. It will grow from $2.98 billion in 2024 to $3.06 billion in 2025 at a compound annual growth rate (CAGR) of 3%. The growth in the historic period can be attributed to improvements in neonatal care practices, increased awareness among healthcare professionals, government initiatives for maternal and child health, research funding and clinical trials, collaborations in medical research.

The kernicterus treatment market size is expected to see steady growth in the next few years. It will grow to $3.37 billion in 2029 at a compound annual growth rate (CAGR) of 2.4%. The growth in the forecast period can be attributed to continuous medical education programs, global health policies and initiatives, patient advocacy and support groups, international collaboration in pediatric research, government funding for neonatal health. Major trends in the forecast period include advancements in neonatal jaundice monitoring technologies, introduction of phototherapy devices with enhanced features, development of bilirubin-reducing medications, focus on home-based phototherapy solutions, implementation of bilirubin nomograms and guidelines, integration of telehealth for remote monitoring.

The rising prevalence of neonatal jaundice is expected to drive the growth of the kernicterus treatment market. Neonatal jaundice, commonly observed in newborns, is typically a benign condition marked by yellowing of the skin and eyes. Kernicterus treatment is often applied in cases of neonatal jaundice to manage symptoms and provide supportive care. This treatment involves exchanging the baby’s blood with blood containing lower bilirubin levels, which enhances the child’s quality of life. For instance, in October 2023, the U.S.-based National Library of Medicine reported that approximately 60% of term infants and 80% of preterm infants develop jaundice within their first week, with about 10% of breastfed infants still showing jaundice at one month. Thus, the widespread occurrence of neonatal jaundice is anticipated to boost the kernicterus treatment market.

Increasing healthcare spending is fueling the growth of the kernicterus treatment market. This type of spending refers to additional investments made in the healthcare sector to address the rising costs associated with expanding or enhancing healthcare services, programs, or infrastructure. Such spending significantly impacts kernicterus treatment by improving the quality and accessibility of care for affected infants and children, leading to better treatment outcomes and an improved quality of life. For example, in November 2023, the Canadian Institute for Health Information reported that total healthcare spending in Canada is expected to reach $344 billion in 2023, or $8,740 per person, marking a 2.8% increase from the prior year’s 1.5% growth rate, signaling a strong resurgence in healthcare investment. Consequently, increased healthcare spending is a driving force behind the growth of the kernicterus treatment market.

Key organizations in the cornea treatment market are increasingly focusing on partnerships to expand their reach and strengthen their competitive position. For example, in July 2024, the UCL Department of Medical Physics and Biomedical Engineering, a UK-based institution known for its contributions to medical physics and biomedical engineering research and education, collaborated with UCL Hospitals, a UK-based healthcare provider, to launch NeoSCB. This smartphone application detects severe jaundice in newborns by analyzing images of the sclera (the white part of the eye), offering a non-invasive screening method. The app is particularly valuable in resource-limited settings where traditional jaundice screening devices are expensive. By measuring the yellowness of the sclera, the app correlates this data with bilirubin levels in the blood, achieving a high accuracy rate by successfully identifying 74 out of 79 infants with severe jaundice. Its performance is comparable to conventional methods, such as transcutaneous bilirubinometers, which measure bilirubin through the skin.

In March 2024, Intermountain Health, a US-based nonprofit healthcare system, formed a partnership with Picterus AS to enhance early jaundice detection for newborns. This collaboration aims to improve health outcomes by offering a non-invasive and accessible screening method. Picterus AS, a healthcare technology company based in Norway, specializes in developing technology for screening and monitoring neonatal jaundice.

Major companies operating in the kernicterus treatment market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, AstraZeneca plc., Abbott Laboratories, Sanofi SA, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Johnson and Johnson Private Limited, Baxter International Inc., Grifols S.A, Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Alembic Pharmaceuticals Limited, Lupin Pharmaceuticals Inc., CSL Limited, Glenmark Pharmaceuticals Ltd., Cipla Inc., Torrent Pharmaceuticals Ltd., Octapharma Brasil Ltda, Kedrion S.p.A, Biotest AG, Wockhardt Ltd., Mylan N.V., Cadila Healthcare Ltd., Teva Pharmaceutical Industries Ltd., China Biologic Products Holdings Inc.

North America was the largest region in the kernicterus treatment market in 2024. The regions covered in the kernicterus treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the kernicterus treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The kernicterus treatment market consists of revenues earned by entities by provide kernicterus treatment services such as diagnostic tests, neurological management, medical evaluation and monitoring and exchange transfusion services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

Kernicterus is an infrequent neurological condition that may manifest in newborns experiencing severe jaundice, marked by elevated levels of bilirubin in the bloodstream. Treatment for kernicterus encompasses medical interventions, therapies, and supportive care, primarily administered to infants and children, with the goal of addressing symptoms, complications, and long-term effects, ultimately enhancing the affected individuals' quality of life.

The primary modalities for treating kernicterus include phototherapy, intravenous immunoglobulins (IVIG), blood transfusion, medication, and other supportive measures. Phototherapy involves the application of light, typically specialized lights or lamps, as a medical intervention. This method is employed to address a range of symptoms associated with kernicterus, such as jaundice, unusual eye movements, vomiting, fever, poor feeding, apnea, irritability, seizures, sleepiness, and others. Dosage administration may take various forms, including injections, solutions, and other delivery methods. The end users of these treatments include clinics, hospitals, and other healthcare facilities.

The kernicterus treatment market research report is one of a series of new reports that provides kernicterus treatment market statistics, including kernicterus treatment industry global market size, regional shares, competitors with a kernicterus treatment market share, detailed kernicterus treatment market segments, market trends and opportunities, and any further data you may need to thrive in the kernicterus treatment industry. This kernicterus treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.